Revolutionary health solutions:The Zealand Approach

Our corporate tag line “revolutionary health solutions” is a reflection of our ambition to design and develop innovative peptide medicines and accompanying solutions which can significantly improve patients’ lives.

Product Revolutionary attributes

Lixisenatide (Lyxumia®

Type 2 diabetes
(licensed to Sanofi)

When lixisenatide was invented by Zealand in 1999 as the first once-daily GLP-1 receptor agonist (RA), the class represented a novel approach in the treatment of Type 2 diabetes with significant benefits over existing types of anti-diabetic treatment:

  • Effective only upon food intake, leading to lower risk of hypos and better beta cell preservation. 
  • First ever diabetes product with weight reducing effect. 
  • GLP-1 receptors are presented in heart tissue, leaving the class with potentially beneficial CV effects – a truly revolutionary aspect.

Lixisenatide has a pronounced lowering effect on post-prandial glucose, uniquely complementing basal insulin as an important new combination therapy to offer patients.

Danegaptide

Ischemia reperfusion injuries (IRI)
(Zealand proprietary product)

Danegaptide is a first-in-class Zealand-invented therapeutic peptide which can protect cells from injury.

Danegaptide has shown a unique ability to reduce tissue damage and infarct sizes in models of IRI, and the peptide has also shown to be very safe. A clinical Phase II Proof-of-Concept study is now ongoing to evaluate the therapeutic effect of danegaptide in the prevention of IRI in patients with a myocardial infarction. 

Cardiac IRI can lead to severely reduced cardiac function and increased cardiac event risk. Treatment options are limited, and we believe danegaptide thus represents significant possible value as the first medicinal approach to improving quality of life for these patients.

If danegaptide can demonstrate positive effect in protecting against cardiac IRI, this will open the potential for broader use of this Zealand peptide also in other forms of IRI, including organ transplants and stroke. 

Elsiglutide

Chemotherapy induced diarrhea
(partnership with Helsinn)

Elsiglutide was invented by Zealand as a novel GLP-2 receptor agonist, a new and upcoming class of medicines with unique characteristics to enhance the function of the gastero-intestinal tract.

In a clinical Phase II study, this peptide has shown the ability to reduce diarrhea in cancer patients treated with chemotherapy. No effective treatment of this condition exists today, leading to reduced quality of life for many cancer patients and non-optimal cancer treatment. 

If the clinical effect of elsiglutide can be firmly established, it opens the possibility not only of significantly improving quality of life for cancer patients, but also for a more effective cancer treatment. This would have a major beneficial impact on patients lives.

Glucagon analoque
optimized for liquid
formulation

Severe hypoglycemia in diabetes
(Zealand proprietary product)

 

Zealand’s innovative team of peptide specialists have invented a glucagon analoque optimized for liquid formulation and with attractive therapeutic properties. This opens the potential for its application in a easy-to-use rescue pen for improved treatment of severe hypoglycemia in diabetes.

Glucagon plays an important role in upregulating blood sugar levels. The peptide is however highly unstable in liquid formulation, and current rescue kits to treat hypoglycemia are therefore based on powder versions of glucagon. This requires a cumbersome handling procedure for relatives in a critial situation.

We believe that an easy-to-use rescue pen with a liquid formulation of glucagon has
the potential to revolutionize the way severe hypoglycemia is treated today with an important positive impact on quality of life for diabetes patients and their relatives.

Further, a liquid formulated glucagon analogue holds potential for use in an artificial closed-loop pancreatic system, which would represent a very important advance in
the treatment of diabetes patients.